ICAM1 and prostate cancer: CD54+ prostate cancer cells exhibited greater tumorigenicity, orb-forming capability, and resistance to the chemotherapeutic agent than CD54– prostate cancer cells through activating the p38-Notch1 signaling pathway (35).